利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.014 秒)

    Human IgG1 derived antibody with pro-apoptotic activity
    3.
    发明授权
    Human IgG1 derived antibody with pro-apoptotic activity 审中-公开

    公开(公告)号：US10669328B2

    公开(公告)日：2020-06-02

    申请号：US15036118

    申请日：2014-11-11

    申请人： OGD2 Pharma

    发明人： Mylene Dorvillius ,  Jean-Marc Le Doussal ,  Mickael Terme

    IPC分类号： C07K16/00 ,  C07K16/32 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00

    摘要： A method for increasing the therapeutic efficacy of a human immunoglobulin G class 1 (IgG1) antibody, includes: mutating the human CH1γ1 domain from the antibody, to restore the pairing between CH1 and CL domains that is typical of the other IgG subclasses, or by substituting the human CH1γ1 domain by the CH1 domain from a human IgG2 (CH1γ2), IgG3 (CH1γ3) or IgG4 (CH1γ4); the antibody obtained by such method, includes a) a light chain including the following amino acid sequences: i) the Light Chain Variable Region (LCVR) specific from an antigen; and ii) a human kappa (κ)Constant (CL) domain; and b) a heavy chain including the following amino acid sequences: i) the Heavy Chain Variable Region (HCVR) specific from the antigen; ii) the CH2 and CH3 domains from a human IgG1; and iii) the CH1 domain from a human IgG1, mutated to restore pairing between CHI and CL domains.

    ANTIBODY AGAINST GD2-O-ACETYLATED GANGLIOSIDE WITH PRO-APOPTOTIC ACTIVITY
    6.
    发明申请
    ANTIBODY AGAINST GD2-O-ACETYLATED GANGLIOSIDE WITH PRO-APOPTOTIC ACTIVITY 审中-公开
    抗GD2-O-乙酰胆碱酯酶与抗病毒活性的抗体

    公开(公告)号：US20160272722A1

    公开(公告)日：2016-09-22

    申请号：US15035979

    申请日：2014-11-11

    申请人： OGD2 PHARMA ,  UNIVERSITE DE NANTES

    发明人： Jean-Marc LE DOUSSAL ,  Mickael TERME ,  Mylene DORVILLIUS

    IPC分类号： C07K16/30

    CPC分类号： C07K16/3084 ,  A61K2039/505 ,  C07K16/3015 ,  C07K16/3023 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

    摘要： Antibody which binds to the O-acetylated-GD2 ganglioside, includes: a) a light chain including three light chain complementary regions (CDRs) having the following amino acid sequences: CDR1: QSLLKNNGNTFL (SEQ id no 1), CDR2: KVS, CDR3: SQSTHIPYT (SEQ id no 2); and a light chain framework sequence from an immunoglobulin light chain, including the human kappa (κ)CL domain; and b) a heavy chain including three heavy chain complementary regions (CDRs) having the following amino acid sequences: CDR1: EFTFTDYY (SEQ id no 3), CDR2: IRNRANGYTT (SEQ id no 4), CDR3: ARVSNWAFDY (SEQ id no 5), and a heavy chain framework sequence from an immunoglobulin heavy chain, including CH2 and CH3 domains from a human IgG1, and a CH1 domain from a human IgG1, which is mutated to restore pairing between CH1 and light chain that is typical of other human IgG subclasses or substituted by a CH1 domain from such non-IgG1 subclasses as human IgG2, IgG3 or IgG4.

    摘要翻译： 与O-乙酰化GD2神经节苷脂结合的抗体包括：a）包含具有以下氨基酸序列的3个轻链互补区（CDR）的轻链：CDR1：QSLLKNNGNTFL（SEQ ID No 1），CDR2：KVS，CDR3 ：SQSTHIPYT（SEQ ID No 2）; 和来自免疫球蛋白轻链（包括人κ（CL））结构域的轻链框架序列; 并且b）包含具有以下氨基酸序列的三个重链互补区（CDR）的重链：CDR1：EFTFTDYY（SEQ ID No 3），CDR2：IRNRANGYTT（SEQ ID No 4），CDR3：ARVSNWAFDY（SEQ ID No 5 ）和来自免疫球蛋白重链的重链框架序列，包括来自人IgG1的CH2和CH3结构域和来自人IgG1的CH1结构域，其被突变以恢复CH1和轻链之间的配对，其是典型的其他人 或由人IgG2，IgG3或IgG4等非IgG1亚类被CH1结构域取代。